Abstract:In the field of medicinal chemistry, the discovery of novel compounds with therapeutic potential is of utmost importance. However, the conventional approach to drug discovery, relying on high-throughput screening (HTS), encounters limitations such as reagent availability and labor costs. Although a hit-finding campaign starts with a virtual screen of millions of compounds, the hit-to-lead and lead optimization stages often require designing, synthesizing, and profiling thousands of analogs before selecting clinical candidates. Recent advances offer an innovative solution - the virtual generation of billions of synthetically feasible compounds with an impressive 80% success rate for synthesis. This breakthrough has the potential to significantly expand the chemical space available for purchase and experimental validation, bringing about a revolution in the field. Our study presents a comprehensive approach to compound discovery and optimization, harnessing quantitative high-throughput screening (qHTS), chemical databases, and reaction-based enumeration. To further enhance the synthesis process and gain deeper insights into compound formation, we utilize the Reaction Cookbook from Biosolveit, which comprises reaction SMARTs for around 300 chemical reactions. By employing this wide range of reactions, we aim to uncover the full spectrum of a chemotype's potential and customize its structure to optimize desired properties. As an illustration of this approach, our work on the ALDH3A1 project resulted in the synthesis of 50 compounds, with 21 of them exhibiting activity (negative curve class values; hit-rate ~42%). Among these active compounds, 6 displayed IC50 values lower than 30 µM and efficacy values less than -50%, with the most potent compound achieving an impressive potency of 447 nM. This study demonstrates the successful synergy between in-silico reaction-based analogs enumeration, molecular modeling and AI/ML-based techniques in identifying compounds with improved biological activity, offering promising prospects for the development of ALDH3A1-targeting agents as potential cancer therapeutics. Computational workflows developed in this study can be used for similar target-based drug discovery campaigns.

Chemistry42: An AI-based platform for de novo molecular design

The Process of AI-Aided Drug Design

REINVENT 2.0: An AI Tool for De Novo Drug Design

Application scenario-oriented molecule generation platform developed for drug discovery

Impact of Artificial Intelligence on Compound Discovery, Design, and Synthesis

The AI-driven Drug Design (AIDD) platform: an interactive multi-parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations

Artificial Intelligence in De novo Drug Design: Are We Still There?

Guided Multi-objective Generative AI to Enhance Structure-based Drug Design

Human-in-the-loop assisted de novo molecular design

AI-chemist for Chemistry Synthesis, Property Characterization, and Performance Testing

Artificial Intelligence for Autonomous Molecular Design: A Perspective

AI-driven drug discovery: identification and optimization of ALDH3A1 selective inhibitors with nanomolar activity

Artificial intelligence and cheminformatics tools: a contribution to the drug development and chemical science

Reinvent 4: Modern AI–driven generative molecule design

MolDesigner: Interactive Design of Efficacious Drugs with Deep Learning

SmartCADD: AI-QM Empowered Drug Discovery Platform with Explainability

Quantum-assisted fragment-based automated structure generator (QFASG) for small molecule design: an in vitro study

FormulationAI: a novel web-based platform for drug formulation design driven by artificial intelligence

DrugFlow: an AI-Driven One-Stop Platform for Innovative Drug Discovery.

An Artificial Intelligence Framework for Optimal Drug Design

dZiner: Rational Inverse Design of Materials with AI Agents